A novel preoperative risk score for predicting Urosepsis after percutaneous nephrolithotomy: validation and clinical application
Urolithiasis · 2025
DOI: 10.1007/s00240-025-01855-5 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Urolithiasis, 2025. Verfasst von Heng Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Henan Provincial People's Hospital, Zhengzhou , 462000, Henan, China. Hauptthemen laut MEDLINE: Nephrolithotomy, Percutaneous, Urinary Tract Infections, Postoperative Complications, Kidney Calculi. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Ganzhou 2020 Guiding Science and Technology Program Project.
Abstract (Originalsprache)
Urinary tract infection (UTI) is a common and serious complication after percutaneous nephrolithotomy (PCNL).This study develops and validates the PuRass scoring system to predict the risk of UTI, including urinary sepsis, after PCNL and support personalized clinical Management. A retrospective analysis of 293 PCNL patients was conducted, incorporating multiple risk factors, including gender, age, diabetes, preoperative white blood cell count, urine analysis and culture results, stone size and type, and the degree of hydronephrosis. Significant risk factors were identified through meta-analysis and integrated into PuRass, with each factor weighted according to its odds ratio (OR) value to establish a quantitative risk assessment model. Results showed that gender, age, diabetes, elevated white blood cell count, and positive urine analysis and culture results significantly increased the risk of post-PCNL UTI. The PuRass model demonstrated excellent predictive performance in ROC curve analysis, achieving 90% sensitivity and 89.4% specificity, with an optimal threshold of 8.5 points. Early intervention strategies based on PuRass effectively reduced infection rates and hospital stays in high-risk patients. This study indicates that PuRass provides a reliable tool for predicting and managing post-PCNL UTI. Future multicenter studies will further validate its clinical applicability and explore its integration with emerging technologies to enhance postoperative management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Henan Provincial People's Hospital, Zhengzhou , 462000, Henan, China.
- Jiangxi Provincial Key Laboratory of Urinary System Diseases, Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang, 330006, Jiangxi, China.
- Department of Ophthalmology, The First Affiliated Hospital, Jiangxi medical college, Nanchang University, Nanchang , 330006, Jiangxi, China.
- Wuhan Integrated Traditional Chinese and Western Medicine Hospital (Wuhan First Hospital), Institute of Urology, Wuhan, 430000, China.
- First Affiliated Hospital of Gannan Medical University, Institute of Urology, Ganzhou, 341000, China.
- Department of Anesthesiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China. ndyfy06109@ncu.edu.cn.
Förderung
- Ganzhou 2020 Guiding Science and Technology Program Project
Zitieren
APA
Yang, H., Chen, Y., Hu, W., Cheng, X., Huang, R., Qian, B., Wang, G., & Huan, F. (2025). A novel preoperative risk score for predicting Urosepsis after percutaneous nephrolithotomy: validation and clinical application. Urolithiasis. https://doi.org/10.1007/s00240-025-01855-5
Vancouver
Yang H, Chen Y, Hu W, Cheng X, Huang R, Qian B, et al. A novel preoperative risk score for predicting Urosepsis after percutaneous nephrolithotomy: validation and clinical application. Urolithiasis. 2025. doi:10.1007/s00240-025-01855-5
BibTeX
@article{Yang2025,
author = {Yang, Heng and Chen, Yujun and Hu, Weiwen and Cheng, Xiaofeng and Huang, Ruohui and Qian, Biao and Wang, Gongxian and Huan, Fu},
title = {A novel preoperative risk score for predicting Urosepsis after percutaneous nephrolithotomy: validation and clinical application},
journal = {Urolithiasis},
year = {2025},
doi = {10.1007/s00240-025-01855-5}
}
EUVIMED